English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: Brain Metastases
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced the presentation of data from a Phase I study (NCT04192981) evaluating concurrent paxalisib and radiation therapy (RT) in patients for the treatment of solid tumor brain metastases (BM) or leptomeningeal metastases (LM) harboring PI3K pathway mutations at the American Society for Radiation Oncology 66th Annual Meeting (ASTRO 2024), which is taking place from September 29 – October 2, 2024, in Washington, D.C.
Socioeconomic disparities in survival outcomes of patients with SCLC with brain metastases: A nationwide analysis
Background:Despite advances in the management of cancer, socioeconomic disparities have been reported to impact survival outcomes. However, recent state of disparities in SCLC patients with brain metastases (BM) remains unknown. We explored socioeconomic disparities in survival outcomes of SCLC BM…
MD Anderson Research Highlights for May 8, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Sylvester Researchers Develop a Nanoparticle That Can Penetrate the Blood-Brain Barrier
Researchers at Sylvester Comprehensive Cancer Center have developed a nanoparticle that can penetrate the blood-brain barrier. Their goal is to kill primary breast cancer tumors and brain metastases in one treatment.
August 2023 Issue of Neurosurgical Focus: “Update on Brain Metastases”
Announcement of contents of the August 2023 issue of Neurosurgical Focus
MD Anderson Research Highlights for July 19, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
New study offers clues to how cancer spreads to the brain
To understand the molecular processes that influence how cancer cells pass through the blood-brain barrier, researchers used two microfluidic chips that mapped cancer cell migration to the brain and looked at what was happening in the blood-brain niche.
MD Anderson Research Highlights for June 29, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.
Combination immunotherapy improves survival for patients with asymptomatic melanoma brain metastases
Combination treatment with immune checkpoint inhibitors nivolumab and ipilimumab demonstrates overall survival for patients with melanoma that has spread to the brain, according to Phase II study results published today in The Lancet Oncology by researchers from The University of Texas MD Anderson Cancer Center.
Radiosurgery reduces cognitive decline without compromising survival for patients with 4+ brain metastases
Results of a new randomized phase III trial suggest that stereotactic radiosurgery (SRS) should replace whole brain radiation therapy (WBRT) as the standard of care for patients with four or more brain metastases. Results from the clinical trial (NCT01592968) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
New tools to improve care for cancer that has spread to the brain
The tools will help doctors and patients make better-informed treatment decisions, enhance the care of brain metastases, and enable hospitals to improve the coordination and effectiveness of their interdisciplinary treatment programs.
FIRE-SCLC analysis: Largest ever study of first-line radiosurgery for brain metastases from small cell lung cancer
The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit from whole-brain radiation compared with radiosurgery in patients with small cell lung cancer.